Adverse Events Associated with CAR-T Therapy

Bleeding or thrombosis occurred in a subset of patients, especially those with higher-grade ICANS.

Chimeric antigen receptor T-cell (CAR-T) therapy has had a profound impact on patients with chemotherapy-refractory B-cell lymphoma or B-acute lymphoblastic leukemia (B-ALL), and it appears promising in patients with multiple myeloma. Certain toxicities are known to be associated with this treatment, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS). However, whether CAR-T therapy increases risk for bleeding or thrombotic consequences is unknown.

To address this issue, investigators conducted a retrospective, single-center analysis of 111 patients with relapsed or refractory diffuse large B-cell lymphoma and 16 patients with B-ALL, all of whom were treated with CAR-T therapy. Of these, 89 …

Reviewing Author

Brady Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Adverse Events Associated with CAR-T Therapy

Topics

Reviewing Author